ClinicalTrials.gg
CompletedNCT00150358Updated Feb 1, 2021

To Yield Further Information On The Efficacy And Safety Of Viagra Among Subjects With Arterial Hypertension .

A Phase 4 interventional study of Sildenafil Citrate in Impotence and Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 16 sites in Mexico. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
253
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing sildenafil in Erectile Dysfunction — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Erectile Dysfunction.

Enrollment
13th of 50
253 · median 108
Started
2005
with 11 others
Phase 4
30 of 50
none open now
Registered
5th of 50
by date
Lead sponsor
23 of 50
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 50 studies testing sildenafil in Erectile Dysfunction, this one is the 13th largest by enrollment, is one of 12 that started in 2005, is one of 30 in phase 4, and was the 5th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

1 of the 50 studies testing sildenafil in Erectile Dysfunction is open now. Recruiting first, the newest first:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing sildenafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

To assess changes with respect to Erectile Dysfunction in subjects treated with Viagra and antihypertensive therapy.

03

Conditions studied

  • Impotence
  • Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with arterial hypertension treated with one or more antihypertensive agents, the doses of which have been stable for at least 4 weeks prior to the baseline visit, with a documented clinical diagnosis of ED and a confirmation of this by a qualification of 21 or less on the SHI-M.

Exclusion criteria

Exclusion Criteria:

  • Subjects with resting sitting systolic blood pressure >170 or \<110mmHg or resting sitting diastolic blood pressure >90 or \<50mmHg, with significant cardiovascular disease and retinitis pigmentosa, treatment with nitrates, alfablockers or inhibitors.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
253 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The primary efficacy measure is the percent of ITT subjects at week 8 with positive response to the Global Efficacy Assessment question regarding the effectiveness of the medication in improving erections over no treatment at all for ED.

Secondary outcomes

  1. The evaluation of change from baseline to week 8 on the toal SHI-M (Sexual Health Inventory-Male) score and the 5 individual items on the SHI-M. Global Efficacy Assessment Questions 2 and 3 at week 8.

07

Study locations

16 sites
  • Pfizer Investigational Site
    Torreon, Coahuila 72000, Mexico
  • Pfizer Investigational Site
    Mexico, DF 07760, Mexico
  • Pfizer Investigational Site
    Guadalajara, Jalisco 44290, Mexico
  • Pfizer Investigational Site
    Colonia Centro, Mexico CITY 06090, Mexico
  • Pfizer Investigational Site
    DF, Mexico City 06760, Mexico
  • Pfizer Investigational Site
    Monterrey, Nuevo Leon 64000, Mexico
  • Pfizer Investigational Site
    Monterrey, Nuevo LEON 64460, Mexico
  • Pfizer Investigational Site
    Merida, Yucatan 97070, Mexico
  • Pfizer Investigational Site
    Aguascalientes, C.P. 20230, Mexico
  • Pfizer Investigational Site
    Chihuahua, 31238, Mexico
  • Pfizer Investigational Site
    Durango, 34300, Mexico
  • Pfizer Investigational Site
    Metepec, 52140, Mexico
  • Pfizer Investigational Site
    Puebla, 72090, Mexico
  • Pfizer Investigational Site
    San Luis Potosi, 78090, Mexico
  • Pfizer Investigational Site
    San Luis PotosÃ-, 78240, Mexico
  • Pfizer Investigational Site
    Veracruz, C.P. 97897, Mexico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 8, 2005
Start
Mar 2005
Completion
Nov 2005
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00150358
Responsible party
Sponsor
First posted
Sep 8, 2005
Start date
Mar 2005
Completion
Nov 2005
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion